JP2020511999A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511999A5 JP2020511999A5 JP2019553818A JP2019553818A JP2020511999A5 JP 2020511999 A5 JP2020511999 A5 JP 2020511999A5 JP 2019553818 A JP2019553818 A JP 2019553818A JP 2019553818 A JP2019553818 A JP 2019553818A JP 2020511999 A5 JP2020511999 A5 JP 2020511999A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tissue
- population
- macrophages
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 27
- 210000002540 macrophage Anatomy 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 10
- 210000001054 cardiac fibroblast Anatomy 0.000 claims description 10
- 210000001808 exosome Anatomy 0.000 claims description 10
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 8
- 210000002744 extracellular matrix Anatomy 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000002798 bone marrow cell Anatomy 0.000 claims description 2
- 210000004958 brain cell Anatomy 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 210000003890 endocrine cell Anatomy 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 210000005003 heart tissue Anatomy 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022205718A JP7419490B2 (ja) | 2017-03-31 | 2022-12-22 | 標的臓器の細胞外構成成分を使用する治療用細胞の作製 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2018628 | 2017-03-31 | ||
| NL2018628 | 2017-03-31 | ||
| PCT/US2018/025371 WO2018183825A1 (en) | 2017-03-31 | 2018-03-30 | Generation of therapeutic cells using extracellular components of target organs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022205718A Division JP7419490B2 (ja) | 2017-03-31 | 2022-12-22 | 標的臓器の細胞外構成成分を使用する治療用細胞の作製 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511999A JP2020511999A (ja) | 2020-04-23 |
| JP2020511999A5 true JP2020511999A5 (https=) | 2021-05-06 |
| JP7249951B2 JP7249951B2 (ja) | 2023-03-31 |
Family
ID=58548819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553818A Active JP7249951B2 (ja) | 2017-03-31 | 2018-03-30 | 標的臓器の細胞外構成成分を使用する治療用細胞の作製 |
| JP2022205718A Active JP7419490B2 (ja) | 2017-03-31 | 2022-12-22 | 標的臓器の細胞外構成成分を使用する治療用細胞の作製 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022205718A Active JP7419490B2 (ja) | 2017-03-31 | 2022-12-22 | 標的臓器の細胞外構成成分を使用する治療用細胞の作製 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11760975B2 (https=) |
| EP (1) | EP3600354B1 (https=) |
| JP (2) | JP7249951B2 (https=) |
| AU (1) | AU2018243554C1 (https=) |
| CA (1) | CA3058437A1 (https=) |
| DK (1) | DK3600354T3 (https=) |
| WO (1) | WO2018183825A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3145493T3 (da) | 2014-05-18 | 2022-10-31 | Childrens Medical Center | Fremgangsmåder og sammensætninger vedrørende exosomer |
| US11738046B2 (en) | 2017-11-03 | 2023-08-29 | Wisconsin Alumni Research Foundation | Macrophage cell therapy to treat orthopedic injury |
| US11499730B2 (en) | 2018-02-12 | 2022-11-15 | Wisconsin Alumni Research Foundation | LPS priming of stromal cells to generate LPS-specific exosome educated macrophages |
| JP7538044B2 (ja) | 2018-04-30 | 2024-08-21 | ザ チルドレンズ メディカル センター コーポレーション | 間葉系間質細胞エキソソームおよびそれらの使用 |
| CA3099042A1 (en) * | 2018-05-09 | 2019-11-14 | Children's Medical Center Corporation | Mesenchymal stromal cell exosome -treated monocytes and uses thereof |
| JP7513284B2 (ja) * | 2019-03-08 | 2024-07-09 | 国立大学法人 新潟大学 | マクロファージの誘導方法、抗炎症性マクロファージの誘導剤及び医薬組成物 |
| EP4135727A4 (en) * | 2020-04-16 | 2024-05-22 | University of Pittsburgh - of the Commonwealth System of Higher Education | MATRIX-BOUND VESICLES (MBV) FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME |
| EP3984527A1 (en) | 2020-10-13 | 2022-04-20 | Ludwig-Maximilians-Universität München | Nano-in-micro encapsulated sirna dry powder, method for producing the same and use of a powder formulation as a pharmaceutical dosage form, in particular for pulmonary delivery |
| US20220127579A1 (en) * | 2020-10-22 | 2022-04-28 | Wisconsin Alumni Research Foundation | Use of Toll-Like Receptor 4 Agonists to Treat Inflammation and Tissue Injury |
| WO2023003775A2 (en) * | 2021-07-21 | 2023-01-26 | The Regents Of The University Of California | Human ipsc-derived macrophages for liver repair and regeneration |
| CA3230583A1 (en) * | 2021-09-07 | 2023-03-16 | Eric Schmuck | Cardiac fibroblast derived extracellular matrix |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120081972A (ko) * | 2009-07-02 | 2012-07-20 | 아이티에이치 임뮨 세라피 홀딩스 에이비 | 엑소좀에 기초한 암의 치료 |
| US8647678B2 (en) * | 2009-08-24 | 2014-02-11 | Wisconsin Alumni Research Foundation | Anti-inflammatory macrophages and uses thereof |
| WO2013028968A1 (en) | 2011-08-25 | 2013-02-28 | Wisconsin Alumni Research Foundation | 3-dimensional cardiac fibroblast derived extracellular matrix |
| WO2015031376A1 (en) * | 2013-08-26 | 2015-03-05 | The Trustees Of Columbia University In The City Of New York | Scaffolds containing cytokines for tissue engineering |
| US10624930B2 (en) | 2014-06-10 | 2020-04-21 | Mesoblast International Sarl | Treatment of immune disorders |
| US10166254B2 (en) | 2014-09-19 | 2019-01-01 | Wisconsin Alumni Research Foundation | Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury |
| US20170304368A1 (en) * | 2014-10-06 | 2017-10-26 | Cedars-Sinai Medical Center | Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells |
| JP7468983B2 (ja) | 2015-06-03 | 2024-04-16 | ウィスコンシン アラムニ リサーチ ファンデーション | 虚血性疾患または虚血性損傷を処置するための心臓線維芽細胞由来細胞外マトリックスおよびその注射可能製剤 |
| US11738046B2 (en) | 2017-11-03 | 2023-08-29 | Wisconsin Alumni Research Foundation | Macrophage cell therapy to treat orthopedic injury |
-
2018
- 2018-03-30 US US15/941,409 patent/US11760975B2/en active Active
- 2018-03-30 CA CA3058437A patent/CA3058437A1/en active Pending
- 2018-03-30 AU AU2018243554A patent/AU2018243554C1/en active Active
- 2018-03-30 DK DK18720454.0T patent/DK3600354T3/da active
- 2018-03-30 JP JP2019553818A patent/JP7249951B2/ja active Active
- 2018-03-30 EP EP18720454.0A patent/EP3600354B1/en active Active
- 2018-03-30 WO PCT/US2018/025371 patent/WO2018183825A1/en not_active Ceased
-
2022
- 2022-12-22 JP JP2022205718A patent/JP7419490B2/ja active Active
-
2023
- 2023-08-17 US US18/451,617 patent/US20230407256A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511999A5 (https=) | ||
| JP2023052043A5 (https=) | ||
| Hassanzadeh et al. | Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities | |
| Zhang et al. | Mesenchymal stem cell-derived extracellular vesicles in tissue regeneration | |
| Xie et al. | What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment? | |
| Sun et al. | Intravenous mesenchymal stem cell-derived exosomes ameliorate myocardial inflammation in the dilated cardiomyopathy | |
| Qiu et al. | Functional proteins of mesenchymal stem cell-derived extracellular vesicles | |
| Wang et al. | MiR-101a loaded extracellular nanovesicles as bioactive carriers for cardiac repair | |
| Cheng et al. | Macrophage polarization as a therapeutic target in myocardial infarction | |
| Napoli et al. | Recent advances in stem cell-based therapeutics for stroke | |
| Lin et al. | The involving progress of MSCs based therapy in atherosclerosis | |
| JP7218947B2 (ja) | 特定の臍帯間葉細胞集団を含む組成物を得る方法およびその使用 | |
| Denburg et al. | The microenvironmental differentiation hypothesis of airway inflammation | |
| Taherian et al. | Stem cell-based therapy for fibrotic diseases: mechanisms and pathways | |
| Suzuki et al. | Unusual cutaneous manifestations of myelodysplastic syndrome | |
| Wang et al. | Apoptotic mesenchymal stem cells and their secreted apoptotic extracellular vesicles: therapeutic applications and mechanisms | |
| Ivosevic et al. | Mesenchymal stem cell–derived extracellular vesicles: new soldiers in the war on immune-mediated diseases | |
| WO2024254540A2 (en) | Treatment of amyotrophic lateral sclerosis with extracellular vesicle composition | |
| Wang et al. | Mesenchymal stem cell-derived exosomes hold promise in the treatment of diabetic foot ulcers | |
| Liu et al. | Distinct molecular properties and functions of small EV subpopulations isolated from human umbilical cord MSCs using tangential flow filtration combined with size exclusion chromatography | |
| JP7120628B2 (ja) | 細胞外小胞による放射線誘発性皮膚炎を予防するまたは治療する方法 | |
| Cui et al. | Therapeutic potential of mesenchymal stem cells in neurodegenerative diseases | |
| Dabravolski et al. | Preclinical and mechanistic perspectives on adipose-derived stem cells for atherosclerotic cardiovascular disease treatment | |
| Chen et al. | Mesenchymal stem cells from different sources for sepsis treatment: prospects and limitations | |
| Alanazi | COVID-19 and the role of stem cells |